Literature DB >> 24396884

Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.

Joseph K Salama, Herbert Pang, Jeffrey A Bogart, A William Blackstock, James J Urbanic, Lydia Hogson, Jeffrey Crawford, Everett E Vokes.   

Abstract

INTRODUCTION: Standard therapy for limited stage small cell lung cancer (L-SCLC) is concurrent chemotherapy and radiotherapy followed by prophylactic cranial radiotherapy. Predictors of post chemoradiotherapy pulmonary toxicity in limited stage (LS) small cell lung cancer (SCLC) patients are not well defined. Current guidelines are derived from non-small cell lung cancer regimens, and do not account for the unique biology of this disease. Therefore, we analyzed patients on three consecutive CALGB LS-SCLC trials treated with concurrent chemotherapy and daily high dose radiotherapy (70 Gy) to determine patient and treatment related factors predicting for post-treatment pulmonary toxicity.
METHODS: Patients treated on CALGB protocols 39808, 30002, 30206 investigating two cycles of chemotherapy followed by concurrent chemotherapy and 70 Gy daily thoracic radiation therapy were pooled. Patient, tumor, and treatment related factors were evaluated to determine predictors of grade 3–5 pulmonary toxicities after concurrent chemoradiotherapy.
RESULTS: 100 patients were included. No patient experienced grade 4–5 post-treatment pulmonary toxicity. Patients who experienced post-treatment pulmonary toxicity were more likely to be older (median age 69 vs 60, p = 0.09) and have smaller total lung volumes (2565 cc vs 3530 cc, p = 0.05).). Furthermore,exposure of larger volumes of lung to lower (median V5 = 70%, p = 0.09, median V10 = 63%, p = 0.07), inter-mediate (median V20 = 50, p = 0.04) and high (median V60 = 25%, p = 0.01) doses of radiation were all associated with post-treatment grade 3 pulmonary toxicity, as was a larger mean lung radiation dose(median 31 Gy) p = 0.019.
CONCLUSION: Post-treatment pulmonary toxicity following the completion of 2 cycles of chemotherapy followed by concurrent chemotherapy and high dose daily radiation therapy was uncommon. Care should be taken to minimize mean lung radiation exposure, as well as volumes of low, intermediate and high doses of radiation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24396884      PMCID: PMC4098705          DOI: 10.1016/j.lungcan.2013.10.001

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

Authors:  Jeffrey A Bogart; James E Herndon; Alan P Lyss; Dorothy Watson; Antonius A Miller; Michael E Lee; Andrew T Turrisi; Mark R Green
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

2.  Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

Authors:  Lester J Peters; Brian O'Sullivan; Jordi Giralt; Thomas J Fitzgerald; Andy Trotti; Jacques Bernier; Jean Bourhis; Kally Yuen; Richard Fisher; Danny Rischin
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.

Authors:  N C Choi; J E Herndon; J Rosenman; R W Carey; C T Chung; S Bernard; L Leone; S Seagren; M Green
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

4.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.

Authors:  A T Turrisi; K Kim; R Blum; W T Sause; R B Livingston; R Komaki; H Wagner; S Aisner; D H Johnson
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

5.  Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.

Authors:  M S Kies; J G Mira; J J Crowley; T T Chen; R Pazdur; P N Grozea; S E Rivkin; C A Coltman; J H Ward; R B Livingston
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

6.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

Authors:  Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Radiotherapy patterns of care study in lung carcinoma.

Authors:  B Movsas; J Moughan; R Komaki; H Choy; R Byhardt; C Langer; M Goldberg; M Graham; D Ettinger; D Johnstone; R Abrams; R Munden; G Starkschall; J Owen
Journal:  J Clin Oncol       Date:  2003-11-03       Impact factor: 44.544

8.  Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.

Authors:  Steven E Schild; James A Bonner; Thomas G Shanahan; Burke J Brooks; Randolph S Marks; Susan M Geyer; Shauna L Hillman; Gist H Farr; Henry D Tazelaar; James E Krook; Francois J Geoffroy; Muhammad Salim; Robert M Arusell; James A Mailliard; Paul L Schaefer; James R Jett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

9.  Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.

Authors:  Michael J Kelley; Jeffrey A Bogart; Lydia D Hodgson; Rafat H Ansari; James N Atkins; Herbert Pang; Mark R Green; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

10.  Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.

Authors:  Antonius A Miller; Xiaofei F Wang; Jeffrey A Bogart; Lydia D Hodgson; Caio M S Rocha Lima; James E Radford; Everett E Vokes; Mark R Green
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609

  10 in total
  3 in total

1.  Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the question.

Authors:  Cesare Gridelli; Francesca Casaluce; Assunta Sgambato; Fabio Monaco; Cesare Guida
Journal:  Transl Lung Cancer Res       Date:  2016-04

2.  Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer.

Authors:  Junhee Park; Min Kyu Kang
Journal:  Radiat Oncol J       Date:  2018-03-30

3.  Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III.

Authors:  Haiyong Wang; Jingze Zhang; Fang Shi; Chenyue Zhang; Qinghua Jiao; Hui Zhu
Journal:  Oncotarget       Date:  2017-05-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.